{
    "clinical_study": {
        "@rank": "161481", 
        "acronym": "PLIS", 
        "arm_group": [
            {
                "arm_group_label": "high risk non-responder,  intensified lifestyle intervention", 
                "arm_group_type": "Active Comparator", 
                "description": "high risk non-responder:\nA) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)\nB) insulin resistance (ISI-Matsuda < 9,2)\nC) elevated liver fat ( MRT > 5,56%)\nA+B or A+C or B+C or A+B+C"
            }, 
            {
                "arm_group_label": "hight risk non responder, normal lifestyle intervention", 
                "arm_group_type": "Active Comparator", 
                "description": "high risk non-responder:\nA) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)\nB) insulin resistance (ISI-Matsuda < 9,2)\nC) elevated liver fat ( MRT > 5,56%)\nA+B or A+C or B+C or A+B+C"
            }, 
            {
                "arm_group_label": "Responder, normal lifestyle intervention", 
                "arm_group_type": "Active Comparator", 
                "description": "Responder:\nA) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)\nB) insulin resistance (ISI-Matsuda < 9,2)\nC) elevated liver fat ( MRT > 5,56%)\nNo A, only B or C"
            }, 
            {
                "arm_group_label": "Responder, single lifestyle advice (control group)", 
                "arm_group_type": "Active Comparator", 
                "description": "Responder:\nA) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)\nB) insulin resistance (ISI-Matsuda < 9,2)\nC) elevated liver fat ( MRT > 5,56%)\nNo A, only B or C"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this prospective randomized  multicenter intervention study is to determine\n      whether in the prevention of Diabetes an intensified lifestyle intervention is superior to a\n      conventional lifestyle intervention in high risk non-Responder subjects. Further, the\n      intensive phenotyping to determine subgroups with an increased risk for diabetes enables an\n      individualized prevention and therapy of type 2 diabetes mellitus."
        }, 
        "brief_title": "Individualized Lifestyle Intervention in Subjects With Prediabetes", 
        "condition": "Diabetes Mellitus Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Glucose Intolerance", 
                "Prediabetic State"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study start with an intensive phenotyping at baseline (initial examination) to determine\n      subjects with prediabetes. These high risk non-Responder are randomized in two arms\n      (intensified vs normal lifestyle intervention)with equal number of subjects (n=250). The\n      results are compared with each other at the end of the study.\n\n      The low risk Responder are randomized in two arms (normal vs. once lifestyle intervention =\n      control group) with equal number of subjects (n=250).\n\n      After the screening at baseline the 12 month lifestyle intervention starts for lifestyle\n      intervention groups. The different therapy groups are formed as described before.  The\n      subjects with intensified lifestyle intervention get 16 consultations, the subjects with\n      normal lifestyle intervention get 8 consultations, the subjects of the control group get one\n      consultation to learn more about a healthier lifestyle. During the whole study there is a\n      continuous supervision from physician and nutritional advisers and the subjects have to\n      document a nutrition and an exercise protocol as well as subjective measurements. At\n      baseline, after 24 weeks and at follow up 1, 2 and 3 years later there is an elaborate\n      metabolic characterization of all subjects (also the Responder groups) a 75 g venous oral\n      glucose tolerance test (OGTT) as well as an analysis of the distribution of body fat\n      confirmed by MR-Imaging and proton magnetic resonance spectroscopy by 3 T whole body imager."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  impaired fasting glucose (IFG)\n\n               -  fasting blood glucose 99-126 mg/dl\n\n        and/or\n\n          -  impaired glucose tolerance (IGT)\n\n               -  75 g OGTT 120 minutes: 139-200 mg/dl\n\n        Exclusion Criteria:\n\n          -  current pregnancy or breastfeeding\n\n          -  BMI > 45 kg/m\u00b2\n\n          -  Diabetes mellitus Typ 1 or 2\n\n          -  serious disease e.g symptomatic coronary heart disease\n\n          -  serious symptomatic malignant disease (weight loss > 10% within the last 6 month)\n\n          -  severe liver or kidney disease ( an increase in transaminases > 3 times than the\n             upper limit of the standardized range, GFR < 50 ml/min/1,73m\u00b2)\n\n          -  systemic infection (CRP > 1 mg/dl)\n\n          -  severe mental illness\n\n          -  drug abuse\n\n          -  treatment with steroids\n\n          -  potentially incompliant subjects\n\n          -  exclusion criteria for magnetic resonance tomography\n\n               -  any kind of metal in or on the body:\n\n                    -  cardiac pacemakers\n\n                    -  prosthetic heart valves\n\n                    -  metal prosthesis\n\n                    -  magnetic implanted metallic parts\n\n                    -  contraceptive coil\n\n                    -  metal fragments/ grenade shrapnel\n\n                    -  fixed braces\n\n                    -  acupuncture needles\n\n                    -  insulin pump\n\n                    -  intraport etc.\n\n                    -  Field strength > 3 Tesla further tattoos, permanent make-up\n\n               -  persons with limited thermosensory or heightened sensitivity to heating\n\n               -  persons where cardiovascular disease cannot be ruled out by examination\n\n               -  persons with heightened sensitivity to  loud noise or diseases of the ear\n\n               -  used closed whole body scanner: claustrophobia\n\n        Additional for spirometry\n\n          -  acute coronary syndrome\n\n          -  higher cardiac arrhythmia\n\n          -  decompensated heart failure\n\n          -  acute carditis\n\n          -  pulmonary embolism\n\n          -  acute deep leg vein thrombosis ( phlebothrombosis)\n\n          -  hyperthyroidism (TSH)\n\n          -  hypokalemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947595", 
            "org_study_id": "DZD-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "high risk non-responder,  intensified lifestyle intervention", 
                "description": "physical activity 6 hours per week, 50% guided activity\nrecorded by an accelerometer (Aipermotion 440)\n16 sessions per year with a lifestyle advisor\nnutritional advice (target weight: 5% less, if BMI > 25kg/m\u00b2, less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)", 
                "intervention_name": "intensified lifestyle intervention", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": [
                    "hight risk non responder, normal lifestyle intervention", 
                    "Responder, normal lifestyle intervention"
                ], 
                "description": "physical activity 3 hours per week\nrecorded by an accelerometer (Aipermotion 440)\n8 sessions per year with a lifestyle advisor\nnutritional advice (target weight: 5% less, if BMI > 25kg/m\u00b2, less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)", 
                "intervention_name": "normal lifestyle intervention", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Responder, single lifestyle advice (control group)", 
                "description": "- Single Health care advice and lifestyle advice (30 minutes) at the beginning\nrecommend the individual target weight (5% less, if BMI 25> kg/m\u00b2)", 
                "intervention_name": "Single lifestyle advice", 
                "intervention_type": "Behavioral"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "diabetes mellitus type 2", 
            "impaired glucose tolerance", 
            "lifestyle intervention", 
            "body fat distribution"
        ], 
        "lastchanged_date": "September 17, 2013", 
        "link": {
            "description": "Click here for more information about this study: research in the DZD --> klinische Studien", 
            "url": "http://www.dzd-ev.de"
        }, 
        "location": [
            {
                "contact": {
                    "email": "gesund.leben@dife.de", 
                    "last_name": "Andreas Pfeiffer, Prof.", 
                    "phone": "004933200-882778"
                }, 
                "contact_backup": {
                    "phone": "004933200-882774"
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Deutsches Institut f\u00fcr Ern\u00e4hrungsforschung / Charit\u00e9 Berlin"
                }, 
                "investigator": {
                    "last_name": "Andreas Pfeiffer, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "peter.schwarz@uniklinikum-dresden.de", 
                    "last_name": "Peter Schwarz, Prof.", 
                    "phone": "0049351-4582715"
                }, 
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany"
                    }, 
                    "name": "University Hospital Dresden"
                }, 
                "investigator": {
                    "last_name": "Peter Schwarz, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "studienzentrum@ddz.uni-duesseldorf.de", 
                    "last_name": "Karsten M\u00fcssig, Prof.", 
                    "phone": "0049211-3382209"
                }, 
                "facility": {
                    "address": {
                        "city": "D\u00fcsseldorf", 
                        "country": "Germany", 
                        "zip": "40225"
                    }, 
                    "name": "Deutsches Diabetes Zentrum"
                }, 
                "investigator": [
                    {
                        "last_name": "Karsten M\u00fcssig, Prof.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Bettina Nowotny, Dr.", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "prevent.diabetes@lrz.uni-muenchen.de", 
                    "last_name": "Anette-Gabriele Ziegler, Prof. Dr.", 
                    "phone": "004989/31874790"
                }, 
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "zip": "85764"
                    }, 
                    "name": "Helmholtz Zentrum M\u00fcnchen"
                }, 
                "investigator": {
                    "last_name": "Anette-Gabriele Ziegler, Prof.Dr.med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "studienzentrum-diabetes@med.uni-muenchen.de", 
                    "last_name": "Jochen Seissler, Prof.", 
                    "phone": "004989-5160-2288"
                }, 
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany"
                    }, 
                    "name": "Ludwig-Maximilians-University"
                }, 
                "investigator": [
                    {
                        "last_name": "Jochen Sei\u00dfler, Prof.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Andreas Lechner, Dr.", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "julia.stoll@tum.de", 
                    "last_name": "Hans Hauner, Prof.", 
                    "phone": "004989-289 249 -16"
                }, 
                "contact_backup": {
                    "email": "julia.petzold@tum.de", 
                    "phone": "004986-289249-25"
                }, 
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "zip": "80333"
                    }, 
                    "name": "Technische Universit\u00e4t M\u00fcnchen (TU Munich)"
                }, 
                "investigator": {
                    "last_name": "Hans Hauner, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Andreas.fritsche@med.uni-tuebingen.de", 
                    "last_name": "Andreas Fritsche, Prof.Dr.med", 
                    "phone": "00497071/29-80590"
                }, 
                "facility": {
                    "address": {
                        "city": "T\u00fcbingen", 
                        "country": "Germany", 
                        "zip": "72076"
                    }, 
                    "name": "University Hospital T\u00fcbingen"
                }, 
                "investigator": [
                    {
                        "last_name": "Andreas Fritsche, Prof.Dr.med.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Norbert Stefan, Prof.Dr.med.", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "4", 
        "official_title": "Prediabetes Lifestyle Intervention Study", 
        "other_outcome": [
            {
                "measure": "metabolic and genetic characterization to determine the risk of type 2 diabetes confirmed by case history, clinical examination, venous blood sampling, DNA isolation, standardised questionnaires, bio-electric impedance analysis (BIA)and ergospirometry", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "metabolic and genetic characterization to determine the non-response to lifestyle intervention confirmed by case history, clinical examination, venous blood sampling, DNA isolation, standardised questionnaires,BIA, ergospirometry", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }
        ], 
        "overall_contact": {
            "email": "Andreas.fritsche@med.uni-tuebingen.de", 
            "last_name": "Andreas Fritsche, Prof.Dr.med", 
            "phone": "00497071/29-5974"
        }, 
        "overall_official": [
            {
                "affiliation": "University Hospital Tuebingen", 
                "last_name": "Andreas Fritsche, Prof. Dr. med", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University Hospital T\u00fcbingen", 
                "last_name": "Norbert Stefan, Prof.Dr.med.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Ministry of Education and Research"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "postprandial glycaemia (2h plasma glucose level of the 75 g oral glucose tolerance test (OGTT))", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947595"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital Tuebingen", 
            "investigator_full_name": "andreas fritsche", 
            "investigator_title": "Prof. Dr. med. Andreas Fritsche", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "insulin resistance is calculated as follows:\nInsulinogenic index (IGI) = (I30 - I0) / (G30 - G0)\nISIest= 10000/\u00b2\u221a ((G0 x I0) x ((G0+G30+G60+G90+G120)/5) x ((I0+I30+I60+I90+I120)/5))", 
                "measure": "insulin sensitivity confirmed by 75 g oral glucose tolerance test (OGTT)", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "insulin resistance is calculated as follows:\nInsulinogenic index (IGI) = (I30 - I0) / (G30 - G0)\nISIest= 10000/\u00b2\u221a ((G0 x I0) x ((G0+G30+G60+G90+G120)/5) x ((I0+I30+I60+I90+I120)/5))", 
                "measure": "insulin secretion confirmed by 75 g oral glucose tolerance test (OGTT)", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "distribution of body fat confirmed by MR-Imaging and proton magnetic resonance spectroscopy by 3 T whole body imager", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }
        ], 
        "source": "University Hospital Tuebingen", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "German Diabetes-Center, Leibniz-Institutt in D\u00fcsseldorf", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Department of Endocrinology and Metabolic Diseases, Charit\u00e9 Berlin", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "German Institute of Human Nutrition (DIfE)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Department of the medical clinic III University Hospital Carl Gustav Carus Dresden", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "LMU M\u00fcnchen, medical clinic IV", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Department of Endocrinology and Metabolism at Heidelberg University Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University Hospital Tuebingen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}